US Patent 11834505 PD-L1-specific antibodies and methods of using the same
Patent 11834505 was granted and assigned to Checkpoint Therapeutics on December, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Infobox (+14 properties)
Article (+512 characters)
US Patent 11834505 PD-L1-specific antibodies and methods of using the same
Article
Patent abstract
The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Jonathan Belk0
Leonid Gorelik0
Nathan J. Sharkey0
Date of Patent
December 5, 2023
0Patent Application Number
168186210
Date Filed
March 13, 2020
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11834505 PD-L1-specific antibodies and methods of using the same
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
